Brief: Frequency Therapeutics Announces First Patient Dosed In Phase 1B Study Of FX-345, Its Second Therapeutic Candidate For Sensorineural Hearing Loss

Korro Bio

15/12/2022 12:45

Dec 15 (Reuters) - Frequency Therapeutics Inc  FREQ.O :
    * FREQUENCY THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
PHASE 1B
STUDY OF FX-345, THE COMPANY’S SECOND THERAPEUTIC CANDIDATE FOR
SENSORINEURAL HEARING LOSS
    * FREQUENCY THERAPEUTICS INC - FREQUENCY'S LEAD HEARING
PROGRAM,
FX-322, ON TRACK FOR PHASE 2B TOPLINE RESULTS IN Q1 2023
    * FREQUENCY THERAPEUTICS INC - REGENERATIVE TREATMENT
DESIGNED TO
INCREASE DRUG EXPOSURE THROUGH COCHLEA; STUDY RESULTS EXPECTED
IN H2 2023

Source text for Eikon:  ID:nBw6ZsjnRa 
Further company coverage:  FREQ.O 
 ((Reuters.Briefs@thomsonreuters.com;))